en
de

Home
About us
Technology
Pipeline
Investors
Press
Contact
Blog
en
de

Home
About us
Memberships

Memberships

MetrioPharm AG

MetrioPharm Memberships

News

MetrioPharm AG Phase II Data in Psoriasis Show Dose-Response - 2019-Oct-16

The data confirm the trend towards clinical efficacy and outstanding safety profile of MP1032, the lead compound from a new class of proprietary immune modulators developed by MetrioPharm AG.

Investor Relations

Investor Relations News QIV 2019 - 2019-Dec-12

Topics: Retrospect 2019, BIO-Europe, Jefferies London Healthcare Conference, Warburg Bank “Meet the future” Conference, Essay by CEO Dr. Wolfgang Brysch: "Who wants to live forever?" (Blog)

Blog

MetrioPharm in the Frankfurter Allgemeine Zeitung - 2020-Jan-09

In December 2019, an article about MetrioPharm was published in the FAZ with the title "Fight against geriatric diseases".

Navigation

Home
About us
Technology
Pipeline
Investors
Press
Contact
Blog

Social

Newsletter

Subscribe to our press releases with the
MetrioPharm PR newsletter

Investors can subscribe to our quaterly corporate information with the
MetrioPharm IR newsletter

Switzerland (HQ)

MetrioPharm AG

Bleicherweg 10
8002 Zurich

Phone: +41 44 562 03 35

Germany (R&D)

MetrioPharm Deutschland GmbH

Am Borsigturm 100
13507 Berlin

Phone: +49 30 3384 395 02

© 2020 MetrioPharm AG
Imprint
Privacy policy
Sitemap